BLDP vs SWBI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BLDP's Piotroski F-Score of 1/9 indicates severe financial distress, with no positive operational or profitability signals, and the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite strong revenue growth (37.2% YoY) and improving earnings surprises in recent quarters, the company remains unprofitable with negative margins and ROE, and its valuation metrics (Price/Sales 7.23, Forward P/E -15.31) reflect speculative pricing. The stock has rebounded sharply (+86.7% over 1 year) but trades at a significant premium to historical lows, with no dividend and neutral insider activity. Analysts maintain a 'hold' recommendation, reflecting cautious optimism amid persistent financial instability.
SWBI exhibits a concerning disconnect between its market price ($14.85) and its deterministic fair value, with a Graham Number of $6.64 and Intrinsic Value of $7.08. While the Piotroski F-Score of 4/9 indicates stable financial health and growth metrics are strong, the valuation is stretched with a P/E of 61.88. Most critically, the dividend payout ratio of 216.67% is fundamentally unsustainable. Despite strong 1-year price momentum, the technical trend has turned sharply bearish (10/100), suggesting a correction toward fair value is likely.
Compare Another Pair
Related Comparisons
BLDP vs SWBI: Head-to-Head Comparison
This page compares Ballard Power Systems Inc. (BLDP) and Smith & Wesson Brands, Inc. (SWBI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.